奇正藏药升级董事会专门委员会 战略投资与ESG深度融合助力可持续发展

Core Points - The company has officially announced the transformation of its "Board Strategic Investment Committee" into the "Board Strategic Investment and ESG Committee," integrating ESG principles into its core decision-making framework [1] - This move aligns with recent regulatory requirements and reflects the growing importance of ESG in the pharmaceutical industry, particularly in relation to public health and capital market recognition [1][2] Group 1: Committee Adjustments - The name change emphasizes the equal importance of ESG alongside strategic investment, moving away from the previous perception of ESG as a secondary concern [2] - The committee's responsibilities have expanded to include five core ESG functions, such as developing top-level ESG planning and assessing ESG impacts on significant company matters [2] - The composition and terms of the committee members remain unchanged to ensure continuity in strategic investment decisions while facilitating the quick implementation of ESG responsibilities [2] Group 2: Industry Leadership - The restructuring represents a systematic leap for the company, building on its years of exemplary ESG practices and providing a replicable model for the Tibetan medicine and ethnic medicine sectors [3] - The company has achieved an ESG A-level rating and has received multiple awards for its ESG efforts, including recognition for its social responsibility and sustainable development initiatives [3] - As of the end of 2024, the company's public welfare foundation has invested a total of 169.2 million yuan in charitable activities, demonstrating a long-term commitment to sustainability and transparency in ESG reporting [3]